Drugs / Zr-DFO-pertuzumab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03109977 | Mar 2017 → Apr 2018 | HER2 positive breast carcinoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Zr-DFO-pertuzumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03109977 ↗ |
| Modality | Diagnostic / imaging agent | “an imaging agent called Zr-DFO-pertuzumab” NCT03109977 ↗ |